Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. Its products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.…
Therma Bright Increases Non-Brokered Private Placement up to $500,000
Therma Bright (CVE: THRM) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 0.0350 CAD on 20 November 2026, down 56.3% over 52 weeks. Its 52-week range is 0.0250 CAD to 0.1100 CAD: the price is 68.2% below the high and 40.0% above the low.
Its market capitalisation is 2.14M CAD.
Therma Bright reports return on equity of 277.3%.
Its debt exceeds its cash by 14.87K CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 1 December 2026.